The role of microenvironment and immunity in drug response in leukemia

被引:66
作者
Bakker, Emyr [1 ]
Qattan, Malak [2 ]
Mutti, Luciano [1 ]
Demonacos, Constantinos [3 ]
Krstic-Demonacos, Marija [1 ]
机构
[1] Univ Salford, Sch Environm & Life Sci, Salford M5 4WT, Lancs, England
[2] King Saud Univ, Riyadh 11451, Saudi Arabia
[3] Univ Manchester, Sch Pharm, Manchester M13 9PL, Lancs, England
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH | 2016年 / 1863卷 / 03期
关键词
Leukemia; Microenvironment; Cancer; Inflammation; Immune surveillance; Novel therapeutics; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; NF-KAPPA-B; BONE-MARROW MICROENVIRONMENT; COMPLEMENT-DEPENDENT CYTOTOXICITY; ACUTE MYELOGENOUS LEUKEMIA; TUMOR-NECROSIS-FACTOR; STROMAL CELLS; T-CELL;
D O I
10.1016/j.bbamcr.2015.08.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Leukemia is a cancer of the white blood cells, with over 54,000 new cases per year diagnosed worldwide and a 5-year survival rate below 60%. This highlights a need for research into the mechanisms behind its etiology and causes of therapy failure. The bone marrow microenvironment, in which adult stem cells are maintained in healthy individuals, has been implicated as a source of chemoresistance and disease relapse. Here the various ways that the microenvironment can contribute to the resistance and persistence of leukemia are discussed. The targeting of the microenvironment by leukemia cells to create an environment more suitable for cancer progression is described. The role of soluble factors, drug transporters, microvesicles, as well as the importance of direct cell cell contact, in addition to the effects of inflammation and immune surveillance in microenvironment-mediated drug resistance are discussed. An overview of the clinical potential of translating research findings to patients is also provided. Understanding of and further research into the role of the bone marrow microenvironment in leukemia progression and relapse are crucial towards developing more effective treatments and reduction in patient morbidity. This article is part of a Special Issue entitled: Tumor Microenvironment Regulation of Cancer Cell Survival, Metastasis, Inflammation, and Immune Surveillance edited by Peter Ruvolo and Gregg L Semenza. Crown Copyright (C) 2015 Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:414 / 426
页数:13
相关论文
共 190 条
[1]   Mechanisms of chemoresistance in cancer stem cells [J].
Abdullah, Lissa Nurrul ;
Chow, Edward Kai-Hua .
CLINICAL AND TRANSLATIONAL MEDICINE, 2013, 2
[2]  
Ajani J.A., 2015, SEMIN ONCOL, V42, P53
[3]   Potential Role of Notch Signalling in CD34+ Chronic Myeloid Leukaemia Cells: Cross-Talk between Notch and BCR-ABL [J].
Aljedai, Abdullah ;
Buckle, Anne-Marie ;
Hiwarkar, Prashant ;
Syed, Farhatullah .
PLOS ONE, 2015, 10 (04)
[4]   The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance [J].
Allavena, Paola ;
Sica, Antonio ;
Garlanda, Cecilia ;
Mantovani, Alberto .
IMMUNOLOGICAL REVIEWS, 2008, 222 :155-161
[5]   MECHANISMS OF CYCLOPHOSPHAMIDE RESISTANCE IN A HUMAN MYELOID-LEUKEMIA CELL-LINE [J].
ANDERSSON, BS ;
MROUE, M ;
BRITTEN, RA ;
FARQUHAR, D ;
MURRAY, D .
ACTA ONCOLOGICA, 1995, 34 (02) :247-251
[6]   Biomarkers for Immunostimulatory Monoclonal Antibodies in Combination Strategies for Melanoma and Other Tumor Types [J].
Ascierto, Paolo A. ;
Kalos, Michael ;
Schaer, David A. ;
Callahan, Margaret K. ;
Wolchok, Jedd D. .
CLINICAL CANCER RESEARCH, 2013, 19 (05) :1009-1020
[7]   Divergent mechanisms of glucocorticoid resistance in experimental models of pediatric acute lymphoblastic leukemia [J].
Bachmann, Petra S. ;
Gorman, Rosemary ;
Papa, Rachael A. ;
Bardell, Jane E. ;
Ford, Jette ;
Kees, Ursula R. ;
Marshall, Glenn M. ;
Lock, Richard B. .
CANCER RESEARCH, 2007, 67 (09) :4482-4490
[8]   Dexamethasone resistance in B-cell precursor childhood acute lymphoblastic leukemia occurs downstream of ligand-induced nuclear translocation of the glucocorticoid receptor [J].
Bachmann, PS ;
Gorman, R ;
MacKenzie, KL ;
Lutze-Mann, L ;
Lock, RB .
BLOOD, 2005, 105 (06) :2519-2526
[9]   Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement [J].
Baig, Nisar A. ;
Taylor, Ronald P. ;
Lindorfer, Margaret A. ;
Church, Amy K. ;
Laplant, Betsy R. ;
Pavey, Emily S. ;
Nowakowski, Grzegorz S. ;
Zent, Clive S. .
LEUKEMIA & LYMPHOMA, 2012, 53 (11) :2218-2227
[10]   Tumor necrosis factor or tumor promoting factor? [J].
Balkwill, F .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :135-141